• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

老年非囊性纤维化支气管扩张症:当前的观点。

Non-cystic fibrosis bronchiectasis in the elderly: current perspectives.

机构信息

Respiratory Department, Royal Infirmary of Edinburgh, Edinburgh, UK,

出版信息

Clin Interv Aging. 2018 Sep 10;13:1649-1656. doi: 10.2147/CIA.S143139. eCollection 2018.

DOI:10.2147/CIA.S143139
PMID:30237701
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6136918/
Abstract

Bronchiectasis is a chronic lung disease with permanently damaged airways predisposing to recurrent respiratory tract infections. There is an increasing prevalence of bronchiectasis in the elderly, affecting approximately 10 patients per 1,000 population. Studies have shown that older, frailer patients tend to have a more severe and symptomatic disease, with those aged 80 and above with worse quality of life, increased hospitalization and increased mortality. These patients will be encountered by clinicians working in all aspects of elderly care. This review covers the various investigations and aspects of treatment for bronchiectasis and how they may be utilized in a more older and generally frailer population.

摘要

支气管扩张症是一种慢性肺部疾病,其气道永久性受损,易发生反复呼吸道感染。老年人中支气管扩张症的患病率不断增加,每 1000 人中约有 10 名患者。研究表明,年龄较大、身体虚弱的患者往往病情更严重、症状更明显,80 岁及以上的患者生活质量更差、住院次数更多、死亡率更高。临床医生在从事老年护理的各个方面工作时都会遇到这些患者。本文综述了支气管扩张症的各种检查和治疗方法,以及如何在年龄更大、身体更虚弱的人群中应用这些方法。

相似文献

1
Non-cystic fibrosis bronchiectasis in the elderly: current perspectives.老年非囊性纤维化支气管扩张症:当前的观点。
Clin Interv Aging. 2018 Sep 10;13:1649-1656. doi: 10.2147/CIA.S143139. eCollection 2018.
2
Characterization of bronchiectasis in the elderly.老年人支气管扩张的特征
Respir Med. 2016 Oct;119:13-19. doi: 10.1016/j.rmed.2016.08.008. Epub 2016 Aug 17.
3
Non-cystic fibrosis bronchiectasis.非囊性纤维化支气管扩张症
J R Coll Physicians Edinb. 2011 Jun;41(2):132-9; quiz 139. doi: 10.4997/JRCPE.2011.217.
4
Non-cystic fibrosis bronchiectasis: diagnosis and management in 21st century.非囊性纤维化性支气管扩张症:21 世纪的诊断与管理。
Postgrad Med J. 2010 Aug;86(1018):493-501. doi: 10.1136/pgmj.2009.091041.
5
Suspecting non-cystic fibrosis bronchiectasis: What the busy primary care clinician needs to know.怀疑非囊性纤维化支气管扩张症:忙碌的基层医疗临床医生需要了解的内容。
Int J Clin Pract. 2017 Feb;71(2). doi: 10.1111/ijcp.12924.
6
Inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchiectasis and chronic lung infection with Pseudomonas aeruginosa (ORBIT-3 and ORBIT-4): two phase 3, randomised controlled trials.吸入性脂质体环丙沙星治疗非囊性纤维化支气管扩张症和慢性铜绿假单胞菌肺部感染患者(ORBIT-3 和 ORBIT-4):两项 3 期随机对照试验。
Lancet Respir Med. 2019 Mar;7(3):213-226. doi: 10.1016/S2213-2600(18)30427-2. Epub 2019 Jan 15.
7
[Emerging bacteria in cystic fibrosis and non-cystic fibrosis bronchiectasis from a microbiologist's perspective].从微生物学家角度看囊性纤维化和非囊性纤维化支气管扩张症中的新兴细菌
Rev Mal Respir. 2020 Sep;37(7):561-571. doi: 10.1016/j.rmr.2020.06.006. Epub 2020 Jul 16.
8
Three clinically distinct chronic pediatric airway infections share a common core microbiota.三种临床不同的慢性儿科气道感染具有共同的核心微生物群。
Ann Am Thorac Soc. 2014 Sep;11(7):1039-48. doi: 10.1513/AnnalsATS.201312-456OC.
9
The efficacy and safety of inhaled antibiotics for the treatment of bronchiectasis in adults: a systematic review and meta-analysis.吸入抗生素治疗成人支气管扩张症的疗效和安全性:系统评价和荟萃分析。
Lancet Respir Med. 2019 Oct;7(10):855-869. doi: 10.1016/S2213-2600(19)30185-7. Epub 2019 Aug 9.
10
Hiatal hernias are correlated with increased severity of non-cystic fibrosis bronchiectasis.膈疝与非囊性纤维化支气管扩张症的严重程度增加相关。
Respirology. 2015 Jul;20(5):749-57. doi: 10.1111/resp.12522. Epub 2015 Apr 14.

引用本文的文献

1
Chest CT scan for the screening of air anomalies at risk of pulmonary barotrauma for the initial medical assessment of fitness to dive in a military population.胸部CT扫描用于筛查军事人员潜水初始健康评估中存在肺气压伤风险的空气异常情况。
Front Physiol. 2022 Oct 7;13:1005698. doi: 10.3389/fphys.2022.1005698. eCollection 2022.
2
Mutagenic damage among bronchiectasis patients attending in the pulmonology sector of a hospital in southern Brazil.巴西南部一家医院肺病科就诊的支气管扩张症患者中的诱变损伤。
Rev Assoc Med Bras (1992). 2022 Sep;68(9):1191-1198. doi: 10.1590/1806-9282.20220178.
3
is an anti-inflammatory bacterium in the respiratory tract of patients with chronic lung disease.是慢性肺病患者呼吸道中的一种抗炎细菌。
Eur Respir J. 2022 May 5;59(5). doi: 10.1183/13993003.01293-2021. Print 2022 May.
4
Determination of the phenotypic age in residents of Mexico City: effect of accelerated ageing on lung function and structure.墨西哥城居民表型年龄的测定:加速衰老对肺功能和结构的影响。
ERJ Open Res. 2020 Aug 25;6(3). doi: 10.1183/23120541.00084-2020. eCollection 2020 Jul.
5
A 2 × 2 factorial, randomised, open-label trial to determine the clinical and cost-effectiveness of hypertonic saline (HTS 6%) and carbocisteine for airway clearance versus usual care over 52 weeks in adults with bronchiectasis: a protocol for the CLEAR clinical trial.一项 2×2 析因、随机、开放标签临床试验,旨在确定高渗盐水(HTS 6%)和羧甲司坦用于气道清除相对于常规护理在 52 周内对支气管扩张症成人的临床和成本效益:CLEAR 临床试验的方案。
Trials. 2019 Dec 19;20(1):747. doi: 10.1186/s13063-019-3766-9.
6
Pulmonary non-tuberculous mycobacterial infections: current state and future management.肺部非结核分枝杆菌感染:现状与未来管理
Eur J Clin Microbiol Infect Dis. 2020 May;39(5):799-826. doi: 10.1007/s10096-019-03771-0. Epub 2019 Dec 18.

本文引用的文献

1
RESPIRE 2: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis.RESPIRE 2 研究:一项比较环丙沙星干粉吸入剂与安慰剂治疗非囊性纤维化支气管扩张症的 III 期、安慰剂对照、随机临床试验。
Eur Respir J. 2018 Jan 25;51(1). doi: 10.1183/13993003.02053-2017. Print 2018 Jan.
2
RESPIRE 1: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis.RESPIRE 1:一项 III 期安慰剂对照随机试验,评估吸入环丙沙星干粉治疗非囊性纤维化支气管扩张症的疗效。
Eur Respir J. 2018 Jan 25;51(1). doi: 10.1183/13993003.02052-2017. Print 2018 Jan.
3
British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD).英国胸科学会非结核分枝杆菌肺病(NTM-PD)管理指南。
Thorax. 2017 Nov;72(Suppl 2):ii1-ii64. doi: 10.1136/thoraxjnl-2017-210927.
4
Palliative Care for Patients with Nonmalignant Respiratory Disease.非恶性呼吸道疾病患者的姑息治疗
Indian J Palliat Care. 2017 Jul-Sep;23(3):341-346. doi: 10.4103/IJPC.IJPC_14_17.
5
Pulmonary exacerbation in adults with bronchiectasis: a consensus definition for clinical research.成人支气管扩张症肺部加重:临床研究的共识定义。
Eur Respir J. 2017 Jun 8;49(6). doi: 10.1183/13993003.00051-2017. Print 2017 Jun.
6
Comorbidities and the risk of mortality in patients with bronchiectasis: an international multicentre cohort study.支气管扩张症患者的合并症与死亡率风险:一项国际多中心队列研究。
Lancet Respir Med. 2016 Dec;4(12):969-979. doi: 10.1016/S2213-2600(16)30320-4. Epub 2016 Nov 16.
7
Characterization of bronchiectasis in the elderly.老年人支气管扩张的特征
Respir Med. 2016 Oct;119:13-19. doi: 10.1016/j.rmed.2016.08.008. Epub 2016 Aug 17.
8
Macrolides for Clinically Significant Bronchiectasis in Adults: Who Should Receive This Treatment?用于治疗成人具有临床意义的支气管扩张症的大环内酯类药物:谁应接受这种治疗?
Chest. 2016 Dec;150(6):1187-1193. doi: 10.1016/j.chest.2016.08.1451. Epub 2016 Aug 31.
9
Pulmonary Rehabilitation in Individuals With Non-Cystic Fibrosis Bronchiectasis: A Systematic Review.非囊性纤维化支气管扩张症患者的肺康复:一项系统评价
Arch Phys Med Rehabil. 2017 Apr;98(4):774-782.e1. doi: 10.1016/j.apmr.2016.05.017. Epub 2016 Jun 16.
10
A longitudinal study characterising a large adult primary ciliary dyskinesia population.一项大型成人原发性纤毛运动障碍人群的纵向研究。
Eur Respir J. 2016 Aug;48(2):441-50. doi: 10.1183/13993003.00209-2016. Epub 2016 Jun 10.